Provided by Tiger Trade Technology Pte. Ltd.

Q32 Bio Inc.

4.18
-0.0600-1.42%
Post-market: 4.180.00000.00%19:39 EST
Volume:122.29K
Turnover:512.20K
Market Cap:50.99M
PE:-0.64
High:4.41
Open:4.28
Low:4.02
Close:4.24
52wk High:6.37
52wk Low:1.35
Shares:12.20M
Float Shares:4.73M
Volume Ratio:0.60
T/O Rate:2.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5785
EPS(LYR):-5.1211
ROE:-491.67%
ROA:-33.50%
PB:-2.76
PE(LYR):-0.82

Loading ...

Company Profile

Company Name:
Q32 Bio Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
26
Office Location:
830 Winter Street,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
- -
Introduction:
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Directors

Name
Position
Jodie Morrison
Chief Executive Officer and Director
Mark Iwicki
Director and Chair
Arthur O. Tzianabos
Director
Bill Lundberg
Director
David Grayzel
Director
Diyong Xu
Director
Isaac Manke
Director
Kathleen LaPorte
Director
Mary Thistle
Director

Shareholders

Name
Position
Jodie Morrison
Chief Executive Officer and Director
Lee Kalowski
Chief Financial Officer and President
Adrien Sipos
Interim Chief Medical Officer
Shelia Violette
Chief Scientific Officer